Becton Dickinson and Company ($BDX) Stock Forecast: Up 2.8% Today

What is Becton Dickinson and Company?

Becton, Dickinson and Co. (BDX) is a renowned medical technology company known for its innovative healthcare solutions. Today, the stock experienced a strong bullish movement in the market.

Why is Becton Dickinson and Company going up?

BDX stock is up 2.8% on Dec 10, 2025 15:35

• An investment firm increased Becton Dickinson's price target to $220 from $215 and maintained a Buy rating, citing positive implications from a transaction with Waters Corporation. This adjustment reflects optimism about the company's future performance.
• The global Pharmacy Automation Systems Market is projected to grow significantly, with key players like BD poised to benefit from the increasing adoption of automation in healthcare.
• Solventum Corporation, a healthcare company spun off from 3M, is garnering attention for its potential turnaround story, which could indirectly impact positively on companies like Becton, Dickinson and Co.
• Despite a reduction in stake by Natixis, institutional investors still hold a significant portion of Becton, Dickinson and Co.'s stock, indicating continued confidence in the company's prospects.

BDX Price Chart

BDX Technical Analysis

BDX News

Jefferies Adjusts PT on Becton, Dickinson and Co. to $220 From $215, Maintains Buy Rating

Jefferies has updated its price target for Becton, Dickinson and Co. (BDX) to $220, an increase from its previous target of $215. The firm has also chosen to maintain its "Buy" rating for the medical technology company. This adjustment reflects Jefferies' continued positive outlook on Becton, Dickinson and Co.'s stock performance.

https://www.marketscreener.com/news/jefferies-adjusts-pt-on-becton-dickinson-and-co-to-220-from-215-maintains-buy-rating-ce7d50dad98df723

Jefferies raises Becton Dickinson stock price target to $220 on deal implications

Jefferies has increased its price target for Becton Dickinson (NYSE:BDX) to $220 from $215, maintaining a Buy rating, due to implications from its transaction with Waters Corporation. The firm notes that investors are "warming up" to the Waters story, supporting Becton Dickinson's stock, and that the "New BD" remaining business appears to be trading at a "relatively cheap pro forma valuation." This adjustment precedes a webinar to discuss the tax-efficient Reverse Morris Trust structure.

https://in.investing.com/news/analyst-ratings/jefferies-raises-becton-dickinson-stock-price-target-to-220-on-deal-implications-93CH-5146391

Pharmacy Automation Systems Market to Reach US$ 12.05 Billion

The global Pharmacy Automation Systems Market, valued at US$ 6.95 billion in 2024, is projected to reach US$ 12.05 billion by 2033, growing at a CAGR of 7.0%. This growth is driven by the increasing adoption of automation in healthcare to improve accuracy, streamline workflows, and reduce operational burdens in pharmaceutical environments. North America currently leads the market with a 46% share, while key players include Arxium, BD, Omnicell, and Parata.

https://www.openpr.com/news/4309396/pharmacy-automation-systems-market-to-reach-us-12-05-billion

Solventum Corporation (SOLV): A Bull Case Theory

This article summarizes a bull thesis on Solventum Corporation (SOLV), a healthcare company recently spun off from 3M. Despite initial high debt, the company has deleveraged significantly through asset sales and is now positioned for a turnaround under strong leadership. The thesis highlights attractive valuation, clear growth targets, and a favorable risk-reward profile for patient investors, while acknowledging risks like potential PFAS litigation.

https://finviz.com/news/249954/solventum-corporation-solv-a-bull-case-theory

Natixis Has $10.33 Million Position in Becton, Dickinson and Company $BDX

Natixis reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 42.9% in Q2, ending with 59,997 shares valued at $10.33 million. Despite this, institutional investors collectively own about 86.97% of the medical instruments supplier's stock. Becton, Dickinson recently increased its quarterly dividend to $1.05 per share, resulting in an annualized dividend of $4.20 and a yield of 2.2%.

https://www.marketbeat.com/instant-alerts/filing-natixis-has-1033-million-position-in-becton-dickinson-and-company-bdx-2025-12-09/

Trending Today

Aave ($AAVE) Crypto Forecast: Down 10.2% Today

Becton Dickinson and Company Price History

01.04.2025 - BDX Stock was down 10.3%

• Despite delivering earnings and revenue surprises in Q2, Becton Dickinson (BDX) experienced a bearish movement in its stock.
• Investors may have been anticipating stronger performance from the company, leading to a sell-off post earnings report.
• The market's negative reaction to projections for key metrics suggests concerns about the company's future growth prospects.
• Overall, the bearish movement in BDX could stem from profit-taking by investors expecting more robust results.

01.04.2025 - BDX Stock was down 14.7%

• BDX posted strong Q1 adjusted EPS, surpassing expectations, but fell short of sales forecasts, causing a negative market response.
• The company's commitment to invest $2.5 billion in enhancing US manufacturing raised concerns about potential cost increases and impacts on future profitability.
• The reduction in fiscal 2025 EPS guidance, attributed to a $0.25 tariff impact, likely influenced investor sentiment negatively.
• Despite outperforming expectations in Q2 earnings, adjustments in overall outlook and guidance appeared to dampen investor enthusiasm, leading to a decline in the stock price.

02.04.2025 - BDX Stock was down 5.0%

• The stock of Becton Dickinson (BDX) experienced a strong bearish movement.
• The potential tariff impact on the company's profit outlook for 2025, coupled with a cut in EPS guidance due to tariff hits, likely contributed to the negative market sentiment.
• Despite posting Q2 earnings that topped estimates, the missed revenue consensus and reduced EPS guidance may have overshadowed the positive earnings surprise, leading to the bearish trend.
• The technical analysis suggesting a possible capitulation in BDX could have added to the selling pressure on the stock as investors reacted to the mixed financial performance and future outlook.

02.04.2025 - BDX Stock was down 8.1%

• BDX stock displayed bearish movement on the market recently.
• Concerns about potential tariff impact on BDX's 2025 profit outlook, leading to a $0.25 decrease in EPS guidance, might have influenced the bearish sentiment.
• Despite exceeding Q2 earnings expectations, BDX fell short of sales consensus and adjusted its EPS guidance, disappointing investors and driving the bearish trend.
• Technical analysis hints at a possible capitulation in BDX, adding to the negative market sentiment and contributing to the stock's decline.

27.10.2024 - BDX Stock was down 1.0%

• BDX experienced a bearish movement possibly due to the news of Embecta, a spinoff company, stopping its insulin patch pump program and planning restructuring.
• Investors might be concerned about the implications of this decision on BDX's overall business strategy and potential impact on future revenue.
• The positive news about Embecta's financial performance and stock jump could have diverted investor attention away from BDX, leading to a decline in BDX's stock price.
• This unexpected development within the healthcare sector could have contributed to the bearish sentiment surrounding BDX today.

07.10.2024 - BDX Stock was down 5.0%

• Despite strong fourth-quarter sales and exceeding revenue estimates, BDX faced a downturn likely attributed to concerns over lower sales expectations in China and market dynamics in the bioscience and pharma sectors.
• The introduction of the BD IO Vascular Access System, designed for quick vascular access in critical care scenarios, did not offset the prevailing market sentiment towards the stock.
• Investors may be evaluating BDX against other companies like MMSI, potentially leading to selling pressure on the stock.
• Although positive earnings surprises were noted, they may not have been enough to counter broader market worries, contributing to BDX's bearish performance despite its robust financial results.

15.00.2025 - BDX Stock was down 1.7%

• The bearish movement in BDX today could be attributed to profit-taking by investors after a period of strong gains or a negative development within the company itself.
• The comparison with Alvotech (ALVO) might have highlighted potential outperformance by ALVO, leading investors to shift their focus and capital away from BDX.
• Market sentiment towards medical stocks as a whole could have shifted, impacting BDX negatively despite its strong fundamentals.
• It's essential for investors to closely monitor any updates regarding BDX's financial performance and strategic initiatives to make informed decisions in light of today's bearish movement.

06.01.2025 - BDX Stock was down 5.1%

• BDX posted impressive Q1 earnings, surpassing revenue and EPS expectations, indicating a strong performance in the last quarter.
• Despite the favorable earnings, the market responded negatively to BDX revising its forecast and revealing plans to split its Biosciences and Diagnostic Solutions business segments.
• Investors may have apprehensions regarding the consequences of this strategic decision and its potential effects on future growth and profitability, influencing the bearish market trend seen in BDX today.

07.07.2025 - BDX Stock was up 7.4%

• BDX stock experienced a strong bullish movement today.
• The company surpassed Q3 earnings and revenue estimates, indicating strong financial performance.
• Despite expectations of declining earnings, BDX managed to deliver positive surprises, boosting investor confidence.
• The better-than-expected performance in key metrics for the quarter ended June 2025 likely contributed to the bullish market movement.

06.10.2025 - BDX Stock was down 0.8%

• Despite surpassing expectations for earnings and revenue in the quarter, BDX witnessed a decline in its stock value.
• The market's reaction might be linked to uncertainties regarding the company's future growth trajectory or provided guidance.
• Investors could be considering broader factors like global economic conditions or developments within the industry, impacting the stock's downward trend.
• The bearish movement could also be influenced by profit-taking activities or prevailing market sentiment, potentially overshadowing the positive earnings outcome.

25.08.2025 - BDX Stock was down 3.9%

• The bearish movement in BDX stock could be attributed to profit-taking by investors after a recent bullish run.
• The initiation of coverage on Biogen (NASDAQ: BIIB) on a bullish note may have diverted attention and funds away from BDX temporarily.
• Market analysts changing their outlook on top names could have influenced investor sentiment towards BDX, leading to the bearish movement.
• Overall, the market movement in BDX today may be a short-term correction influenced by external factors rather than any fundamental issues with the company itself.

10.11.2025 - BDX Stock was up 2.8%

• An investment firm increased Becton Dickinson's price target to $220 from $215 and maintained a Buy rating, citing positive implications from a transaction with Waters Corporation. This adjustment reflects optimism about the company's future performance.
• The global Pharmacy Automation Systems Market is projected to grow significantly, with key players like BD poised to benefit from the increasing adoption of automation in healthcare.
• Solventum Corporation, a healthcare company spun off from 3M, is garnering attention for its potential turnaround story, which could indirectly impact positively on companies like Becton, Dickinson and Co.
• Despite a reduction in stake by Natixis, institutional investors still hold a significant portion of Becton, Dickinson and Co.'s stock, indicating continued confidence in the company's prospects.